57
Participants
Start Date
May 8, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2029
Regorafenib (BAY 73-4506)
Regorafenib will be administered a starting dose of 80 mg per day with weekly 40 mg per day increases to a maximum of 120 mg per day for 3 weeks on / 1 week off continued until disease progression or unacceptable toxic effects occurred or consent was withdrawn, up to 12 cycles of treatment.
5FU/LV
5FU/LV administered as (LV \[400 mg/m² IV over 120 minutes\], followed by 5FU \[400 mg/m² IV bolus then 2400 mg/m² IV infusion over 46 hours\] in 2-week cycles)
Bevacizumab
Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered intravenously on days 1 and 15.
Trifluridine-tipiracil
FTD-TPI, administered orally, BID, at a starting dose of 35 mg/m2 of body-surface area, on days 1 through 5 and on days 8 through 12 every 28 days.
RECRUITING
Houston Methodist Neal Cancer Center, Houston
The Methodist Hospital Research Institute
OTHER